Table 4.
Risk predictors of all-cause mortality after SPM diagnosis by the TNM stage or stage groups of SPMs and surgical treatment among all patients with solid SPM*.
| Unadjusted HR (95%CI) § | P-value | Adjusted HR (95%CI)# | P-value | |
|---|---|---|---|---|
| Invasion of SPM ǂ | ||||
| Local | 1 reference | 1 reference | ||
| Regional | 2.19 (1.92-2.50) | <0.001 | 1.59 (1.37-1.84) | <0.001 |
| Distant | 9.13 (8.06-10.33) | <0.001 | 3.83 (3.28-4.47) | <0.001 |
| AJCC stage group of SPM ǂ | ||||
| I | 1 reference | 1 reference | ||
| II | 0.89 (0.77-1.04) | 0.129 | 1.32 (1.10-1.59) | 0.003 |
| III | 2.55 (2.16-3.00) | <0.001 | 2.02 (1.70-2.41) | <0.001 |
| IV | 7.03 (6.10-8.11) | <0.001 | 3.95 (3.34-4.67) | <0.001 |
| AJCC T stage of SPM ¶ | ||||
| T1 | 1 reference | 1 reference | ||
| T2 | 1.46 (1.27-1.68) | <0.001 | 1.45 (1.25-1.68) | <0.001 |
| T3/T4 | 3.44 (3.02-3.91) | <0.001 | 1.66 (1.42-1.93) | <0.001 |
| Ta/Tis | 0.91 (0.70-1.19) | 0.500 | 0.42 (0.29-0.60) | <0.001 |
| AJCC N stage of SPM ¶ | ||||
| N0 | 1 reference | 1 reference | ||
| N1 | 2.22 (1.91-2.60) | <0.001 | 1.15 (0.97-1.38) | 0.112 |
| N2 | 5.37 (4.57-6.30) | <0.001 | 1.61 (1.33-1.95) | <0.001 |
| N3 | 8.19 (6.20-10.83) | <0.001 | 2.06 (1.51-2.80) | <0.001 |
| AJCC N stage of SPM ¶ | ||||
| M0 | 1 reference | 1 reference | ||
| M1 | 7.50 (6.66-8.45) | <0.001 | 2.41 (2.09-2.79) | <0.001 |
| Surgical treatment for SPM | ||||
| NO | 1 reference | 1 reference | ||
| Yes | 0.35 (0.32-0.39) | <0.001 | 0.40 (0.35-0.46) | <0.001 |
SPM, second primary malignancy; CI, confidence interval; AJCC, American Joint Committee on Cancer system; RCC, renal cell carcinoma; T, Tumor; N, lymph node; M, Metastasis.
*All SPM in solid malignancy (n= 5008) exclude acute/chronic leukemia/myeloma, melanoma of the skin, NHL/Hodgkin, miscellaneous.
§ Univariate Cox proportional risk regression analysis.
#Multivariate analysis with covariables adjusted (age at the time of diagnosis of SPM, sex, race, marital status, population, region, family income, tumor grade, histological type of first primary RCC, tumor size of first primary RCC, tumor TNM stage [or stage groups], time-to-SPM, types of SPM, and treatment of RCC and SPM).
ǂ Invasion of SPM and AJCC TNM stage groups were separately included in the multivariate Cox proportional risk regression with other covariables.
¶ AJCC T, N, M were together included in the Cox proportional risk regression.